Pioglitazone the treatment of schizophrenia

The effect of pioglitazone on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110281556N30

Enrollment

Registered

2011-10-29

Start date

2011-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. schizophrenia

Interventions

Intervention 1: Tablets Risperidone (6 mg/day) combined with Tablets placebo as control group for 8 weeks. Intervention 2: Tablet Risperidone (6 mg/day) combined with 30 mg per day pioglitazone as int

Treatment - Drugs

Placebo

Tablets Risperidone (6 mg/day) combined with Tablets placebo as control group for 8 weeks

Tablet Risperidone (6 mg/day) combined with 30 mg per day pioglitazone as intervention group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: age between 18-50 years old; diagnosis of Schizophrenia based on DSM IV; chronic Schizophrenia( duration of the disorder>2 years); minimum Score of 60 on Positive and Negative Scale; being treated with a stable dose of risperidone for at least 8 weeks and clinically stable for at least 4 weeks prior to entry. Exclusion Criteria: substance dependence; IQ <70; any other mental disorder on axis I; any serious medical or neurological problem; receiving ECT during the last 14 days and hepatic or renal diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026